Jia Ruan, M.D., Ph.D.

Medical Oncology
Jia Ruan

Jia Ruan, M.D., Ph.D., is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medical College. Dr. Ruan graduated summa cum laude from Washington University in St. Louis. She received comprehensive training in medicine and immunology leading to combined MD-PhD degrees from the Tri-Institutional Medical Scientist TrainingProgram of Cornell University, the Rockefeller University and Sloan-Kettering Cancer Institute. She completed internship and residency in internal medicine and started a clinical fellowship in Hematology at the Stanford University Medical Center. Returning to Cornell, Dr. Ruan completed a fellowship in Hematology and Medical Oncology at the New York Presbyterian Hospital. She is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ruan's clinical practice includes patients with lymphoma, myeloma, and other hematological disorders.

Following her long-standing interest in tumor immunology and vascular medicine, Dr. Ruan is actively involved in clinical and translational research aimed at development of novel therapeutics targeting tumor microenvironment.  Her research efforts have been recognized and supported by competitive fundings from Cornell CARCC, the Lymphoma Research Foundation, the ASCO Foundation Young Investigator Award and the ASCO Foundation Junior Faculty Career Development Award, in addition to the K08 Clinical Scientist Career Development Award from the National Institute of Health (NHLBI).

Education B.A. Washington University in St. Louis, 1992 Ph.D. Cornell University Graduate School of Medical Sciences, 1998 M.D. Weill Cornell Medical College, 1999 Professional Training 1999-2000 Intern, Department of Medicine, Stanford University Medical Center 2000-2001 Resident, Department of Medicine, Stanford University Medical Center 2002-2003 Fellow, Division of Hematology, Stanford University Medical Center 2003-2005 Fellow, Division of Hematology-Oncology, New York Presbyterian Hospital, Weill Cornell Medical Center Faculty Positions 2005-present Assistant Professor of Medicine, Weill Cornell Medical College 2005-present Assistant Attending Physician, New York Presbyterian Hospital Professional Memberships American Society of Hematology American Society of Clinical Oncology Honors/Awards Phi Beta Kappa Summa cum laude in Biochemistry and Molecular Biology, Washington University Richard Lounsbery Foundation Fellowship Ezekiel Marion Foster M.D. Medical Scientist Fellowship Alpha Omega Alpha Franklyn Ellenbogen Prize in Hematology-Oncology, Cornell class of '99 Fellow's Teaching Award, Division of Hematology, Stanford Medical Center ASH Clinical Research Training Institute (CRTI) Fellowship ASCO Young Investigator Award ASCO Career Development Award NIH / NHLBI K08 Award

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

Original Research

Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, Osborne J, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, Leonard JP, Kaminski MS. (2014) Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leuk Lymphoma. 2014 Apr 15. [Epub ahead of print]

Ruan, J., Gregory, S.A., Christos, P., Martin, P., Furman, R.R., Coleman, M., Leonard, J.P. (2014) Long-term follow-up of R-CHOP with Bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clin Lymphoma Myeloma Leuk. 14(2):107-13.

Song, K., Herzog, B.H., Sheng, M., Fu, J., McDaniel, J.M., Ruan, J., Xia, L. (2013) Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 73(24):7254-64.

Zhu, Q., Wang, H., Ruan, J., Guo, L., Zhao, S., Zhang, W., Wang, Q., Jin, Z., Chen, X., Sun, A., Wu, D., Han, Y. (2013) Analysis of prognostic factors for survival in 75 Chinese patients with peripheral T-cell lymphoma. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print]

Ruan, J., Luo, M., Wang, C., Fan, L., Yang, S.N., Cardenas, M., Geng, H., Leonard, J.P., Melnick, A., Cerchietti, L., Hajjar, K.A. (2013) Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 27;121(26):5192-202.

Wang, X., Dai, H., Wang, Q., Wang, Q., Xu, Y., Wang, Y., Sun, A., Ruan, J., Chen, S., Wu, D. (2013) EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. PLoS One. 8(4):e61341.

Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, Gergis U. (2012) Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 87(4):433-5.

Elstrom, R.L., Andemariam, B., Martin, P., Ruan, J., Shore, T.B., Coleman, M., Leonard, J.P., Furman, R.R. (2012). Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 53(8):1469-73.

Ruan, J., Martin, P., Furman, R.R., Lee, S.M., Cheung, K., Vose, J.M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., Chadburn, A., Cesarman, E., Coleman, M., Leonard, J.P. (2011) Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-Cell lymphoma and mantle cell lymphoma. J Clin Oncol. 29(6):690-7.

Furman, R.R., Martin, P., Ruan, J., Cheung, Y.K., Vose, J.M., LaCasce, A.S., Elstrom, R., Coleman, M., Leonard, J.P. (2010) Phase I trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 116(23):5432-9.

Ruan, J., Martin, P., Coleman, M., Furman, R., Faye, A., Cheung, K., Elstrom, R., Lachs, M., Hajjar, K. A., Leonard, J. P. (2010) Durable responses with the metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma. Cancer. 116(11):2655-64.

Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., Diliberto, M., Melnick, A., Knowles, D.M., Chen-Kiang, S., Coleman, M., Leonard, J.P. (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 27(8):1209-13.

Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M. A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E. J., Shore, T. B., Schuster, M. W., Ely, S., Knowles, D. M., Chen-Kiang, S., Coleman, M., Leonard, J. P. (2008) Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of Oncology. 19(7):1327-30.

Coleman, M., Martin, P., Ruan, J., et al (2008) The PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Relapsing Refractory Lymphoma: Low Dose Metronomic, Multidrug Therapy. Cancer. 112(10):2228-32.

Coleman, M., Martin, P., Ruan, J., et al. (2008) Low Dose Metronomic Multidrug Therapy with the PEPC (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Mantle Cell Lymphoma. Leukemia & Lymphoma. 49(3):447-50.

Ruan, J., Hyjek, E., Kermani, P., Christos, P.J., Ikalowych, S., Coleman, M., Hempstead, B., Leonard, J.P., Chadburn, A. and Rafii, S. (2006) Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin Lymphoma. Clin Cancer Res. 12(19):5622-31.

Gotlib, J., Berubé, C., Growney, J. D., Chen, C.-C., George, T. I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S. L., Durocher, J. A., Lichy, J. H., Wang, Y., Cohen, P. S., Arber, D., Heinrich, M. C., Neckers, L., Galli, S. J., Gilliland, D. G., and Coutré, S. E. (2005) Activity of the Tyrosine Kinase Inhibitor PKC412 in a Patient with Mast Cell Leukemia with the D816V KIT Mutation. Blood. 106(8):2865-70.

St John, G., Brot, N., Ruan, J., Erdjument-Bromage, H., Tempst, P., Weissbach, H., Nathan, C. (2001) Peptide Methionine Sulfoxide Reductase from Escherichia coli and Mycobacterium tuberculosis Protects Bacteria against Oxidative Damage from Reactive Nitrogen Intermediates. Proc Natl Acad Sci U S A 98(17):9901-6.

Ruan, J., St John, G., Ehrt, S., Riley, L., Nathan, C. (1999) noxR3, a Novel Gene from Mycobacterium tuberculosis, Protects Salmonella typhimurium from Nitrosative and Oxidative Stress. Infect. Immun. 67:3276-83.

Ehrt, S., Shiloh, M. U., Ruan, J., Choi, M., Gunzburg, S., Nathan, C., Xie, Q.-w., and Riley, L. W. (1997) An Antioxidant Gene from Mycobacterium tuberculosis. J. Exp. Med. 186: 1885-96.

Shiloh, M. U., Ruan, J., and Nathan, C. (1997) Evaluation of Bacterial Survival and Phagocytes Function with a Fluorescence-Based Microplate Assay. Infect. Immun. 65:3193-98.

Ruan, J., Xie, Q-w., Hutchinson, N., Cho, H., Wolfe, G. C., and Nathan, C. (1996) Inducible Nitric Oxide Synthase Requires Both the Canonical Calmodulin-binding Domain and Additional Sequences in Order to Bind Calmodulin and Produce Nitric Oxide in the Absence of Free Ca. J. Biol. Chem. 271:22679-86.

Review Articles

Ruan, J. (2011) Antiangiogenic therapies in non-Hodgkin lymphoma. Curr Cancer Drug Targets. 2011 Nov;11(9):1030-43.

Ruan, J., Coleman, M., Leonard, J.P. (2009) Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology. 23(8): 683-90.

Ruan, J., Leonard, J.P. (2009) Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leuk Lymphoma. 50(5):679-81.

Ruan, J., Hajjar, K. A., Rafii, S., Leonard, J. P. (2009) Angiogenesis and anti-angiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol. 20(3):413-24.

Leonard, J. P., Martin, P., Ruan, J., Elstrom, R., Barrientos, J., Coleman, M., Furman, R. R. (2008) New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of Oncology. Suppl 4:iv60-2.

Martin, P., Furman, R. R., Ruan, J., Elstrom, R., Barrientos, J., Niesvizky, R., Coleman, M., Leonard, J. P. (2008) Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in Hematology. 45(2):126-32.

Leonard, J.P., Ruan, J., Martin, P., Coleman, M., Furman, R.R. (2007) New Agents in Development for Non-Hodgkin's Lymphoma. Seminars in Hematology. 44:S18-21.

Ruan, J. and Leonard, J. P. (2006) Mantle cell lymphoma: Current Concepts in Biology and Treatment. Cancer Treatment and Research. 131:141-59.

Leonard, J. P., Furman, R. R., Ruan, J., Coleman, M. (2005) New Developments in Immunotherapy for Non-Hodgkin's Lymphoma. Current Oncology Reports. 7(5):364-71.

Book Chapter

Ruan, J. and Hajjar, H.A. Fibrinolysis and Thrombolysis, Chapter 136, Williams Hematology 8th edition, 2010.

Meeting Abstracts

Ruan, J., Q-w. Xie, N. Hutchinson, H. Cho, G. C. Wolfe, and C. Nathan. Calmodulin (CaM) binding region of mouse nitric oxide synthase-2 (residues 503-532) is necessary but not sufficient for CaM binding and nitric oxide production at trace calcium. American Society for Biochemistry and Molecular Biology Meeting, New Orleans, LA., June 2-6, 1996 (poster presentation).

Ruan, J., S. Ehrt, M. Shiloh, Q.-w. Xie, L. Riley, and C. Nathan. Anti-oxidant/anti-nitrosative gene from Mycobacterium tuberculosis: functional characterization in E. coli and S. typhimurium. The 5th International Meeting on Biology of Nitric Oxide. Kyoto, Japan, September 15-19, 1997 (podium presentation).

Gotlib, J., Berube, C., Ruan, J., Growney, J., Dugan, K., Falkow, R., Rosamilia, M., Resta, D., Cohen, P., Fabbro, D., Heinrich, M., Gilliland, D.G., Coutre, S. PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. American Society of Hematology Annual Meeting, San Diego, CA, December 6-9, 2003 (poster presentation).

Ruan, J., Hyjek, E., Hooper, A.T., Vincent, L., Kermani, P., Christos, P.J., Ikalowych, S., Coleman, M., Hempstead, B., Leonard, J.P., Chadburn, A. and Rafii, S. Magnitude of Stromal Incorporation of VEGFR-1 , CD68 and alpha-SMA Hemangiogenic Cells Distinguishes Histologic Subtypes of Non-Hodgkin#146;s Lymphoma. American Society of Hematology Annual Meeting, Atlanta, GA, December 10-13, 2005 (poster presentation).

Ruan, J., Coleman, M., Furman, R.R., Glynn, P., Joyce, M., Ketas, J., Cheung, K., Church, S., Shore, T., Feldman, E.J., Rutherford, S.C., Hyjek, E., Chadburn, A., Rafii, S., and Leonard, J.P. Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease. American Society of Hematology Annual Meeting, Orlando, FL, December 9-12, 2006 (poster presentation).

Hajjar, K.A., Ruan, J., Sui, G., Deora, A.B., Church, S., Cohen-Gould, L., Rafii, S., Lyden, D.C., Ling, Q. Annexin 2 Mediates Plasminogen-Related Recruitment of Neovascular Mural Cells in Lymphoma Angiogenesis. American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2007 (poster presentation)

Ruan, J., Coleman, M., Furman, R. R., Martin, P., Glynn, P., Joyce, M., Goodwin, J., Cheung, K., Feldman, E., Schuster, M., Shore, T., Leonard, J. P. Durable responses with the anti-angiogenic metronomic regimen RT-PEPC in recurrent mantle cell lymphoma (MCL). Lugano lymphoma meeting, Lugano, Switzerland, June 2008.

Ruan, J., Martin, P., Coleman, M., Furman, R., Glynn, P., Joyce, M., Cheung, K., Shore, T., Schuster, M., Leonard, J. Durable Responses with the Anti-Angiogenic Metronomic Regimen RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma (MCL). American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2009 (Abs 8525)

Ruan, J., Martin, P., Furman, R.R., Vose, J.M., LaCasce, A., Cheung, Y.K., O'Loughlin, J., Elstrom, R., Niesvizky, R., Chadburn, A., Ely, S., Cesarman, E., Coleman, M., Leonard, J.P. CHOP-R Bortezomib as initial therapy for mantle cell lymphoma (MCL). American Society of Hematology Annual Meeting. New Orleans, LA 2009.

Ruan, J., Ward, M., Fan, L., Faye, A., Lane, M., Hajjar, K., Tyrell, L., Martin, P., Elstrom, R., Coleman, M., Furman, R.R., and Leonard, J.P. Levels of circulating endothelial cells and endothelial progenitors correlate with disease status and treatment response in human lymphoma subtypes of CLL and MCL. American Society of Hematology Annual Meeting. New Orleans, LA 2009.

Ruan, J., Mark, T., Allan, J., Morrison, J., Koirala, A., Martin, P., Coleman, C., Lachs, M., Niesvizky, R., Leonard, J.P. Elderly patients with lymphoma and myeloma can effectively participate in clinical trials of novel agents. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2010.

Ruan, J., Cerchietti, L., Wang, C., Fan, L., Yang, S., Geng, H., Leonard, J.P., Melnick, A., Hajjar, K.A.  Therapeutic targeting of lymphoma-associated vascular pericytes.  American Society of Hematology Annual Meeting.  San Diego, CA 2011.

Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S., Furman, R.R., Christos, P., Rodriguez, A., Wolstencroft, P., Svoboda, J., Bender, A., Lewis, J., Coleman, M., Leonard, J.P.  Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi-center phase II study of lenalidomide plus rituximab.  American Society of Hematology Annual Meeting.  New Orleans, LA 2013.

Honors and Awards

Phi Beta Kappa (1992)

Alpha Omega Alpha (1998)

ASCO Foundation Young Investigator Award (2005)

ASCO Foundation Junior Faculty Career Development Award (2007)

T. Franklin Williams Scholar (2007)

NIH/NHLBI K08 Clinical Scientist Career Development Award (2008)